Charles joined SV in 2018 and is a member of the biotechnology investment team, particularly focusing on new company creation. He serves as a board observer at Zarodex, Autifony Therapeutics, Mestag Therapeutics and has helped SV invest in Imbria Pharmaceuticals, as well as incubate and launch Mestag Therapeutics.
Additionally, Charles is involved with ongoing fund portfolio management, due diligence of new deals, and providing strategic, BD, and operational support to existing companies in the SV portfolio.
Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies.
Outside of SV, Charles is a keen chef, swimmer, and traveller.
MSci Human Genetics, University College London; specialization in the genetics of neurodegenerative disease and cancer biology. Chartered accountant (ACA).